GAO Considers FDA Data Insufficient To Predict FY 2005 Review Performance
This article was originally published in The Gray Sheet
Executive Summary
The high volume of fiscal 2003 and 2004 submissions still pending at FDA precludes a thorough assessment of whether the agency will be able to meet FY 2005 device review performance goals under MDUFMA, according to the Government Accountability Office
You may also be interested in...
Sandoz Pioneers Posaconazole And Silodosin In Canada
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
Amarin Pulls Insurer Into Hikma/Vascepa Induced Infringement Suit
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Dutch Supplements Firm Caught Buying Fake Instagram Followers
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: